Novo Nordisk AS (WBO:NNO2) Degree of Operating Leverage : 1.26 (As of Mar. 2026)


WBO:NNO2 Novo Nordisk AS WBO:NNO2
71 GF Score
Price €43.06
GF Value €120.14
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Degree of Operating Leverage?

Novo Nordisk AS WBO:NNO2 -1.23% 71 Degree of Operating Leverage is 1.26 as of Mar. 2026. GuruFocus rates WBO:NNO2 with a GF Score™ of 71/100 and a GF Value™ of €120.14 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 933 Drug Manufacturers companies, Novo Nordisk AS ranks worse than 52.95% on this metric.

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Novo Nordisk AS's Degree of Operating Leverage for the quarter that ended in Mar. 2026 was 1.26. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Novo Nordisk AS's Degree of Operating Leverage or its related term are showing as below:

WBO:NNO2's Degree of Operating Leverage is ranked worse than
52.95% of 933 companies
in the Drug Manufacturers industry
Industry Median: 1.08 vs WBO:NNO2: 1.26

Novo Nordisk AS  (WBO:NNO2) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Novo Nordisk AS Degree of Operating Leverage Related Terms


Novo Nordisk AS Degree of Operating Leverage Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Degree of Operating Leverage Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.99 0.67 1.69 1.15 -0.04

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 1.65 1.17 -0.04 1.26

WBO:NNO2 vs LLY, JNJ, ABBV: Degree of Operating Leverage Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS Degree of Operating Leverage vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Degree of Operating Leverage falls into.


WBO:NNO2
71GF Score
Novo Nordisk AS WBO:NNO2
Degree of Operating Leverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Degree of Operating Leverage Calculation

Novo Nordisk AS's Degree of Operating Leverage for the quarter that ended in Mar. 2026 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( 21404.273 (Mar. 2026) / 19435.709 (Mar. 2025) - 1 )/( 43898.397 (Mar. 2026) / 40641.526 (Mar. 2025) - 1 )
=0.1013/0.0801
=1.26***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

What does a Degree of Operating Leverage of 1.26 mean?
Novo Nordisk AS (WBO:NNO2) has a Degree of Operating Leverage of 1.26 as of Mar. 2026. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Novo Nordisk AS and its competitors. According to the industry distribution chart, Novo Nordisk AS ranks #494 out of 933 companies in the Drug Manufacturers industry, placing it in the top 52.9%.
Is Novo Nordisk AS's Degree of Operating Leverage too high?
Novo Nordisk AS's current Degree of Operating Leverage is 1.26. The Drug Manufacturers industry median Degree of Operating Leverage is 1.08. Novo Nordisk AS's value of 1.26 is 16.7% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #494 out of 933 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Novo Nordisk AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Degree of Operating Leverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #494 out of 933 companies for Degree of Operating Leverage. This places Novo Nordisk AS in the lower half of its industry. The industry median Degree of Operating Leverage is 1.08. Novo Nordisk AS's value of 1.26 is 16.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Operating Leverage for a Drug Manufacturers company?
The median Degree of Operating Leverage among Drug Manufacturers companies is 1.08, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a Degree of Operating Leverage significantly above this median, while those in the bottom quartile fall well below. However, Degree of Operating Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Degree of Operating Leverage of 1.26 is 16.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Operating Leverage mean?
A high Degree of Operating Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Degree of Operating Leverage is 1.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Degree of Operating Leverage is 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €120.14, compared to a current price of €43.06 — trading 64.2% below its estimated fair value. The current Degree of Operating Leverage is 1.26 and 16.7% above the Drug Manufacturers industry median of 1.08. Novo Nordisk AS's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Operating Leverage calculated?
Degree of Operating Leverage is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Degree of Operating Leverage is 1.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.06 is trading 64.2% below its estimated GF Value™ of €120.14. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for WBO:NNO2:

  • Degree of Operating Leverage: 1.26
  • GF Value™: €120.14 vs. price of €43.06 (64.2% below fair value)
  • GF Score™: 71/100 with 4 warning signs
  • Industry Position: 16.7% above the Drug Manufacturers median (#494 of 933)

No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score

Get the complete analysis for WBO:NNO2

Degree of Operating Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.06
Price
€120.14
GF Value